These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Donor-derived soluble HLA plasma levels can not be used to monitor graft rejection in heart transplant recipients. Koelman CA; Vaessen LM; Balk AH; Weimar W; Doxiadis II; Claas FH Transpl Immunol; 2000 Mar; 8(1):57-64. PubMed ID: 10834611 [TBL] [Abstract][Full Text] [Related]
23. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Billen EV; Christiaans MH; Lee J; van den Berg-Loonen EM Transplantation; 2009 Feb; 87(4):563-9. PubMed ID: 19307795 [TBL] [Abstract][Full Text] [Related]
24. Increased concentration of soluble human leukocyte antigen class I levels in the bronchoalveolar lavage of human pulmonary allografts. Rizzo M; Sundaresan S; Lynch J; Trulock EP; Cooper J; Patterson GA; Mohanakumar T J Heart Lung Transplant; 1997 Nov; 16(11):1135-40. PubMed ID: 9402513 [TBL] [Abstract][Full Text] [Related]
25. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. Lones MA; Czer LS; Trento A; Harasty D; Miller JM; Fishbein MC J Heart Lung Transplant; 1995; 14(1 Pt 1):151-62. PubMed ID: 7727464 [TBL] [Abstract][Full Text] [Related]
26. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch. Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518 [TBL] [Abstract][Full Text] [Related]
27. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855 [TBL] [Abstract][Full Text] [Related]
28. [Pathology of heart transplantation.(Morphological study of 1246 endomyocardial biopsies from 167 transplanted hearts). Causes of early, intermediate, and late deaths]. Agozzino L; Thomopoulos K; Esposito S; Agozzino M; De Vivo F; Maiello C; Cotrufo M Pathologica; 1999 Apr; 91(2):89-100. PubMed ID: 10484868 [TBL] [Abstract][Full Text] [Related]
29. The presence of donor-specific human leukocyte antigen antibodies does not preclude successful withdrawal of tacrolimus in stable renal transplant recipients. Kreijveld E; Hilbrands LB; van Berkel Y; Joosten I; Allebes W Transplantation; 2007 Nov; 84(9):1092-6. PubMed ID: 17998862 [TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of in vitro propagation of activated lymphocytes from endomyocardial biopsy samples of pediatric heart transplant recipients. Webber SA; Bentlejewski C; Park A; Fricker FJ; Griffith C; Boyle GJ; Miller SA; Pham S; Murali S; Griffith BP; Duquesnoy R; Zeevi A Pediatr Transplant; 1998 Aug; 2(3):200-5. PubMed ID: 10084743 [TBL] [Abstract][Full Text] [Related]
31. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI Clin Transpl; 2006; ():241-53. PubMed ID: 18365382 [TBL] [Abstract][Full Text] [Related]
32. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. Koskinen PK; Krogerus LA; Nieminen MS; Mattila SP; Häyry PJ; Lautenschlager IT J Heart Lung Transplant; 1993; 12(3):343-54. PubMed ID: 8392371 [TBL] [Abstract][Full Text] [Related]
33. Reliability and usefulness of immunofluorescence in heart transplantation. Bonnaud EN; Lewis NP; Masek MA; Billingham ME J Heart Lung Transplant; 1995; 14(1 Pt 1):163-71. PubMed ID: 7727465 [TBL] [Abstract][Full Text] [Related]
34. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat: virus-induced expression of major histocompatibility complex class II antigens. You XM; Steinmüller C; Wagner TO; Bruggeman CA; Haverich A; Steinhoff G J Heart Lung Transplant; 1996 Nov; 15(11):1108-19. PubMed ID: 8956120 [TBL] [Abstract][Full Text] [Related]
35. The avidity, not the mere presence, of primed cytotoxic T-lymphocytes for donor human leukocyte class II antigens determines their clinical relevance after heart transplantation. van Emmerik NE; Loonen EH; Vaessen LM; Balk AH; Mochtar B; Claas FH; Weimar W J Heart Lung Transplant; 1997 Feb; 16(2):240-9. PubMed ID: 9059936 [TBL] [Abstract][Full Text] [Related]
37. [Endomyocardial biopsy in the heart transplant patient: the state of the art]. Arbustini E; Grasso M; Diegoli M; Gavazzi A; Campana C; Martinelli L; Goggi C; Pucci A; Grossi P; Ippoliti G G Ital Cardiol; 1991 Oct; 21(10):1107-23. PubMed ID: 1804749 [TBL] [Abstract][Full Text] [Related]